Inflation Re-Emergence | AbbVie's Humira, Disney Streaming, Intel's Issues | Triple Play Ep. 7

Posted: Feb. 16, 2023, 12:23 p.m.

Blue Line Capital president Bill Baruch and analyst Jannis Meindl lay out the landscape across macro post-CPI. With consumer and producer prices surprising to the upside, the Fed might be cornered as housing and economic data writ large remains solid. We also talk about 3 stocks, all of which have their unique tailwinds & headwinds. AbbVie just lost its U.S. patent for its blockbuster drug Humira, Disney tries to make streaming profitable while spending billions, and Intel aims to restore its iconic brand name after a rough quarterly earnings report.

Don't hesitate to connect with our sister-company, Blue Line Capital.

We provide free access to the episode's chart-pack, including all of the data discussed.


0:00 - Macro Discussion - Housing Data, Inflation & Economy

5:46 - AbbVie - Replacing $20bn of Humira Sales

10:51 - Disney - The Ultimate Story Telling Brand

16:48 - Intel - An Iconic Chip Brand With Struggles


Bill Baruch is the founder and CEO of Blue Line Capital. All opinions expressed by Bill and podcast guests are solely their own opinions and are not intended to provide specific advice or recommendations. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions. Understand your financial condition before investing. Blue Line Capital, its staff, or its clients may maintain positions in the securities discussed in this podcast.

Sign up for a 14-day, no-obligation free trial of our proprietary research with actionable ideas!
Free Trial Start Trading with Blue Line Futures Subscribe to our YouTube Channel
Email [email protected] or call 312-278-0500 with any questions -- our trade desk is here to help with anything on the board!

Futures trading involves substantial risk of loss and may not be suitable for all investors. Therefore, carefully consider whether such trading is suitable for you in light of your financial condition. Trading advice is based on information taken from trade and statistical services and other sources Blue Line Futures, LLC believes are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Trading advice reflects our good faith judgment at a specific time and is subject to change without notice. There is no guarantee that the advice we give will result in profitable trades. All trading decisions will be made by the account holder. Past performance is not necessarily indicative of future results.

Blue Line Futures is a member of NFA and is subject to NFA’s regulatory oversight and examinations. However, you should be aware that the NFA does not have regulatory oversight authority over underlying or spot virtual currency products or transactions or virtual currency exchanges, custodians or markets. Therefore, carefully consider whether such trading is suitable for you considering your financial condition.

With Cyber-attacks on the rise, attacking firms in the healthcare, financial, energy and other state and global sectors, Blue Line Futures wants you to be safe! Blue Line Futures will never contact you via a third party application. Blue Line Futures employees use only firm authorized email addresses and phone numbers. If you are contacted by any person and want to confirm identity please reach out to us at [email protected] or call us at 312- 278-0500

Macro Semiconductors Streaming Pharma

Like this post? Share it below:

Back to Insights